Gaertner, Jan ORCID: 0000-0002-1176-3164, Stamer, Ulrike M., Remi, Constanze ORCID: 0000-0001-7655-0306, Voltz, Raymond, Bausewein, Claudia ORCID: 0000-0002-0958-3041, Sabatowski, Rainer ORCID: 0000-0003-2228-3147, Wirz, Stefan, Mueller-Mundt, Gabriele, Simon, Steffen T., Pralong, Anne, Nauck, Friedemann, Follmann, Markus ORCID: 0000-0003-3790-5578, Radbruch, Lukas and Meissner, Winfried (2017). Metamizole/dipyrone for the relief of cancer pain: A systematic review and evidence-based recommendations for clinical practice. Palliat. Med., 31 (1). S. 26 - 35. LONDON: SAGE PUBLICATIONS LTD. ISSN 1477-030X
Full text not available from this repository.Abstract
Background: Dipyrone (metamizole) is one of the most widely used non-opioid analgesics for the treatment of cancer pain. Aim: Because evidence-based recommendations are not yet available, a systematic review was conducted for the German Guideline Program in Oncology to provide recommendations for the use of dipyrone in cancer pain. Design: First, a systematic review for clinical trials assessing dipyrone in adult patients with cancer pain was conducted. Endpoints were pain intensity, opioid-sparing effects, safety, and quality of life. Data sources: The search was performed in MedLine, Embase (via Ovid), and the Cochrane Library (1948-2013) and additional hand search was conducted. Finally, recommendations were developed and agreed in a formal structured consensus process by 53 representatives of scientific medical societies and 49 experts. Results: Of 177 retrieved studies, 4 could be included (3 randomized controlled trials and 1 cohort study, n=252 patients): dipyrone significantly decreased pain intensity compared to placebo, even if low doses (1.5-2g/day) were used. Higher doses (3x2g/day) were more effective than low doses (3x1g/day), but equally effective as 60mg oral morphine/day. Pain reduction of dipyrone and non-steroidal anti-inflammatory drugs did not differ significantly. Compared to placebo, non-steroidal anti-inflammatory drugs, and morphine, the incidence of adverse effects was not increased. Conclusion: Dipyrone can be recommended for the treatment of cancer pain as an alternative to other non-opioids either alone or in combination with opioids. It can be preferred over non-steroidal anti-inflammatory drugs due to the presumably favorable side effect profile in long-term use, but comparative studies are not available for long-term use.
Item Type: | Journal Article | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Creators: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
URN: | urn:nbn:de:hbz:38-247586 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DOI: | 10.1177/0269216316655746 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal or Publication Title: | Palliat. Med. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Volume: | 31 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number: | 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Page Range: | S. 26 - 35 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Date: | 2017 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Publisher: | SAGE PUBLICATIONS LTD | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Place of Publication: | LONDON | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ISSN: | 1477-030X | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Language: | English | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Faculty: | Unspecified | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Divisions: | Unspecified | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subjects: | no entry | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Uncontrolled Keywords: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Refereed: | Yes | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
URI: | http://kups.ub.uni-koeln.de/id/eprint/24758 |
Downloads
Downloads per month over past year
Altmetric
Export
Actions (login required)
View Item |